BLACK DIAMOND THERAPEUTICS INC reports a Return on Equity (ROE) of -41.43%.

What is BDTX's dividend yield?

BLACK DIAMOND THERAPEUTICS INC offers a dividend yield of 0.00%.

What is BDTX's Deepscope Quality Score?

Deepscope rates BDTX's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy BDTX?

Deepscope's AI Timing Score for BDTX is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does BDTX belong to?

BLACK DIAMOND THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

BDTX (NASDAQ) Stock Analysis | BLACK DIAMOND THERAPEUTICS INC

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-02 | FS: 2026-03-31)

BDTX

BLACK DIAMOND THERAPEUTICS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 88

USD 2.18

-0.08 (-3.54%) Day Change

Watchlist Portfolio Compare Chart

0.04

D/E

-41.4%

ROE

-32.5%

ROA

0.00%

Div Yield

BLACK DIAMOND THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 2.18 Price -0.08 (-3.54%) Day Change	NEWS SCORE: 88

BDTX, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

41%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	88
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	2.18
PBV / Sector	1.24 / 4.53 GOOD
Earning Per Share	-0.73

PE / Sector	N/A / 16.80
PEG or PE/Growth / Sector	N/A / 0.51
Average 1M Daily Value	6.05 M
Average 1W Daily Value	3.41 M GREAT

Timing Factors

14%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 450.37
NPM Average (%) / Sector	31.95 / -1,506.30 GREAT
NPM Change Average (%) / Sector	N/A / 4,941.44
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-32.51 / 30.83
ROA Average (%) / Sector	-36.80 / -347.12
ROA Change Average (%) / Sector	-109.25 / 5,126.35
ROE (%) / Sector	-41.43 / -3.04
ROE Average (%) / Sector	-50.92 / 40.76
ROE Change Average (%) / Sector	-105.90 / 2,110.63
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 4.43

Registration Details

Analyze Date	2026-06-03 09:11:27
Symbol	BDTX
Name	BLACK DIAMOND THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	57.30 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	129.50 / 8,614.17

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 245 First Street, Cambridge, MA, United States, 02142

Phone: 617 252 0848

Website: https://www.blackdiamondtherapeutics.com

Sector: Healthcare >> Biotechnology

Description: Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.